Efficacy and safety of short-term administration of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis

B. W. Ramsey, S. J. Astley, M. L. Aitken, W. Burke, Andrew Colin, H. L. Dorkin, J. D. Eisenberg, R. L. Gibson, I. R. Harwood, D. V. Schidlow, R. W. Wilmott, M. E. Wohl, L. J. Meyerson, S. Shak, H. Fuchs, A. L. Smith

Research output: Contribution to journalArticle

199 Citations (Scopus)

Abstract

Chronic endobronchial bacterial infection evokes purulent airway secretions in patients with CF. The viscoelastic properties of these secretions is primarily due to the presence of polymerized DNA from degenerating leukocytes. Recombinant human DNase I (rhDNase) reduces the viscosity of CF sputum in vitro. To test the hypothesis that rhDNase would improve pulmonary function in children and adults with CF, we compared the efficacy and safety of 10-day administration of three doses of aerosolized rhDNase (0.6, 2.5, or 10.0 mg twice daily) in 181 outpatients using a randomized, placebo-controlled parallel design. Forced vital capacity (FVC) improved 10 to 12% (p < 0.05 to 0.001), and forced expiratory volume in one second (FEV1) improved 10 to 15% (p < 0.001) across all doses of rhDNase compared with placebo. The magnitude of effect was dose dependent for both FVC and FEV1 through study Day 21 (p < 0.001). rhDNase was associated with a decreased perception of dyspnea and an improved perception of well-being. No patients developed detectable anti-rhDNase antibodies or bronchial reactivity to rhDNase. Some patients experienced mild upper airway irritation, but no major adverse events were reported. Administration for 10 days of aerosolized rhDNase to pediatric and adult outpatients with CF improves lung function and is well tolerated. Although all three doses were efficacious, the greatest improvement in FEV1 and FEV1/FVC ratio was demonstrated in the 2.5 and 10.0 mg rhDNase treatment groups.

Original languageEnglish
Pages (from-to)145-151
Number of pages7
JournalAmerican Review of Respiratory Disease
Volume148
Issue number1
StatePublished - Jan 1 1993
Externally publishedYes

Fingerprint

Deoxyribonucleases
Deoxyribonuclease I
Cystic Fibrosis
Safety
Vital Capacity
Outpatients
Placebos
dornase alfa
Lung
Forced Expiratory Volume
Sputum
Bacterial Infections
Viscosity
Dyspnea
Leukocytes
Pediatrics
Antibodies
DNA

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Ramsey, B. W., Astley, S. J., Aitken, M. L., Burke, W., Colin, A., Dorkin, H. L., ... Smith, A. L. (1993). Efficacy and safety of short-term administration of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis. American Review of Respiratory Disease, 148(1), 145-151.

Efficacy and safety of short-term administration of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis. / Ramsey, B. W.; Astley, S. J.; Aitken, M. L.; Burke, W.; Colin, Andrew; Dorkin, H. L.; Eisenberg, J. D.; Gibson, R. L.; Harwood, I. R.; Schidlow, D. V.; Wilmott, R. W.; Wohl, M. E.; Meyerson, L. J.; Shak, S.; Fuchs, H.; Smith, A. L.

In: American Review of Respiratory Disease, Vol. 148, No. 1, 01.01.1993, p. 145-151.

Research output: Contribution to journalArticle

Ramsey, BW, Astley, SJ, Aitken, ML, Burke, W, Colin, A, Dorkin, HL, Eisenberg, JD, Gibson, RL, Harwood, IR, Schidlow, DV, Wilmott, RW, Wohl, ME, Meyerson, LJ, Shak, S, Fuchs, H & Smith, AL 1993, 'Efficacy and safety of short-term administration of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis', American Review of Respiratory Disease, vol. 148, no. 1, pp. 145-151.
Ramsey, B. W. ; Astley, S. J. ; Aitken, M. L. ; Burke, W. ; Colin, Andrew ; Dorkin, H. L. ; Eisenberg, J. D. ; Gibson, R. L. ; Harwood, I. R. ; Schidlow, D. V. ; Wilmott, R. W. ; Wohl, M. E. ; Meyerson, L. J. ; Shak, S. ; Fuchs, H. ; Smith, A. L. / Efficacy and safety of short-term administration of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis. In: American Review of Respiratory Disease. 1993 ; Vol. 148, No. 1. pp. 145-151.
@article{7e43388b4b31403bbcc923e7f3bcad8d,
title = "Efficacy and safety of short-term administration of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis",
abstract = "Chronic endobronchial bacterial infection evokes purulent airway secretions in patients with CF. The viscoelastic properties of these secretions is primarily due to the presence of polymerized DNA from degenerating leukocytes. Recombinant human DNase I (rhDNase) reduces the viscosity of CF sputum in vitro. To test the hypothesis that rhDNase would improve pulmonary function in children and adults with CF, we compared the efficacy and safety of 10-day administration of three doses of aerosolized rhDNase (0.6, 2.5, or 10.0 mg twice daily) in 181 outpatients using a randomized, placebo-controlled parallel design. Forced vital capacity (FVC) improved 10 to 12{\%} (p < 0.05 to 0.001), and forced expiratory volume in one second (FEV1) improved 10 to 15{\%} (p < 0.001) across all doses of rhDNase compared with placebo. The magnitude of effect was dose dependent for both FVC and FEV1 through study Day 21 (p < 0.001). rhDNase was associated with a decreased perception of dyspnea and an improved perception of well-being. No patients developed detectable anti-rhDNase antibodies or bronchial reactivity to rhDNase. Some patients experienced mild upper airway irritation, but no major adverse events were reported. Administration for 10 days of aerosolized rhDNase to pediatric and adult outpatients with CF improves lung function and is well tolerated. Although all three doses were efficacious, the greatest improvement in FEV1 and FEV1/FVC ratio was demonstrated in the 2.5 and 10.0 mg rhDNase treatment groups.",
author = "Ramsey, {B. W.} and Astley, {S. J.} and Aitken, {M. L.} and W. Burke and Andrew Colin and Dorkin, {H. L.} and Eisenberg, {J. D.} and Gibson, {R. L.} and Harwood, {I. R.} and Schidlow, {D. V.} and Wilmott, {R. W.} and Wohl, {M. E.} and Meyerson, {L. J.} and S. Shak and H. Fuchs and Smith, {A. L.}",
year = "1993",
month = "1",
day = "1",
language = "English",
volume = "148",
pages = "145--151",
journal = "American Journal of Respiratory and Critical Care Medicine",
issn = "1073-449X",
publisher = "American Thoracic Society",
number = "1",

}

TY - JOUR

T1 - Efficacy and safety of short-term administration of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis

AU - Ramsey, B. W.

AU - Astley, S. J.

AU - Aitken, M. L.

AU - Burke, W.

AU - Colin, Andrew

AU - Dorkin, H. L.

AU - Eisenberg, J. D.

AU - Gibson, R. L.

AU - Harwood, I. R.

AU - Schidlow, D. V.

AU - Wilmott, R. W.

AU - Wohl, M. E.

AU - Meyerson, L. J.

AU - Shak, S.

AU - Fuchs, H.

AU - Smith, A. L.

PY - 1993/1/1

Y1 - 1993/1/1

N2 - Chronic endobronchial bacterial infection evokes purulent airway secretions in patients with CF. The viscoelastic properties of these secretions is primarily due to the presence of polymerized DNA from degenerating leukocytes. Recombinant human DNase I (rhDNase) reduces the viscosity of CF sputum in vitro. To test the hypothesis that rhDNase would improve pulmonary function in children and adults with CF, we compared the efficacy and safety of 10-day administration of three doses of aerosolized rhDNase (0.6, 2.5, or 10.0 mg twice daily) in 181 outpatients using a randomized, placebo-controlled parallel design. Forced vital capacity (FVC) improved 10 to 12% (p < 0.05 to 0.001), and forced expiratory volume in one second (FEV1) improved 10 to 15% (p < 0.001) across all doses of rhDNase compared with placebo. The magnitude of effect was dose dependent for both FVC and FEV1 through study Day 21 (p < 0.001). rhDNase was associated with a decreased perception of dyspnea and an improved perception of well-being. No patients developed detectable anti-rhDNase antibodies or bronchial reactivity to rhDNase. Some patients experienced mild upper airway irritation, but no major adverse events were reported. Administration for 10 days of aerosolized rhDNase to pediatric and adult outpatients with CF improves lung function and is well tolerated. Although all three doses were efficacious, the greatest improvement in FEV1 and FEV1/FVC ratio was demonstrated in the 2.5 and 10.0 mg rhDNase treatment groups.

AB - Chronic endobronchial bacterial infection evokes purulent airway secretions in patients with CF. The viscoelastic properties of these secretions is primarily due to the presence of polymerized DNA from degenerating leukocytes. Recombinant human DNase I (rhDNase) reduces the viscosity of CF sputum in vitro. To test the hypothesis that rhDNase would improve pulmonary function in children and adults with CF, we compared the efficacy and safety of 10-day administration of three doses of aerosolized rhDNase (0.6, 2.5, or 10.0 mg twice daily) in 181 outpatients using a randomized, placebo-controlled parallel design. Forced vital capacity (FVC) improved 10 to 12% (p < 0.05 to 0.001), and forced expiratory volume in one second (FEV1) improved 10 to 15% (p < 0.001) across all doses of rhDNase compared with placebo. The magnitude of effect was dose dependent for both FVC and FEV1 through study Day 21 (p < 0.001). rhDNase was associated with a decreased perception of dyspnea and an improved perception of well-being. No patients developed detectable anti-rhDNase antibodies or bronchial reactivity to rhDNase. Some patients experienced mild upper airway irritation, but no major adverse events were reported. Administration for 10 days of aerosolized rhDNase to pediatric and adult outpatients with CF improves lung function and is well tolerated. Although all three doses were efficacious, the greatest improvement in FEV1 and FEV1/FVC ratio was demonstrated in the 2.5 and 10.0 mg rhDNase treatment groups.

UR - http://www.scopus.com/inward/record.url?scp=0027278897&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027278897&partnerID=8YFLogxK

M3 - Article

VL - 148

SP - 145

EP - 151

JO - American Journal of Respiratory and Critical Care Medicine

JF - American Journal of Respiratory and Critical Care Medicine

SN - 1073-449X

IS - 1

ER -